Evid Based Nurs 8:18 doi:10.1136/ebn.8.1.18
  • Treatment

Review: chemotherapy plus supportive care improves survival and quality of life in advanced or metastatic gastrointestinal cancer more than supportive care alone

Chemotherapy plus supportive care (SC) v SC alone for patients with gastrointestinal cancer*

Patients’ conditions Number of patients Comparison Survival p Value
*CR  =  colorectal; CHT  =  chemotherapy; combination CHT  =  5-FU, leucovorin, and cisplatin; ELF  =  5-FU, leucovorin, and etoposide; FLv  =  5-FU and leucovorin.
†Patients could receive SC.
‡Significant only after correction for imbalances in pretreatment characteristics.
Advanced CR and stomach cancer refractory to CHT 107 Octreotide† v SC 20 v 11 weeks <0.0001
Metastatic CR cancer that progressed within 6 months of treatment with fluorouracil 279 Irinotecan plus SC v SC 9.2 v 6.5 months 0.0001
Previously untreated, inoperable, locally recurrent or metastatic CR cancer 36 Combination CHT plus SC v SC 11 v 5 months 0.006
Advanced, surgically incurable stomach cancer 61 ELF or FLv plus SC v SC 8 v 5 months 0.003‡

This Article

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBN.
View free sample issue >>

EBN Journal Chat

The EBN Journal Chat offers readers the opportunity to participate in discussion about research articles and commentaries from Evidence Based Nursing (EBN).

How to participate >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article